Samsung Biologics has achieved ISO 37301:2021 certification for the first time.

The company also renewed certifications for upgraded ISO 27001:2022 and ISO 27017:2015 standards.

The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics' headquarters.

ISO 37301:2021, the leading standard for a Compliance Management System, reflects the company's commitment to enhancing organizational governance and complying with laws and regulations. Samsung Biologics operates a Compliance Program that promotes a culture of integrity and effectively addresses challenges in a rapidly evolving business environment as a reliable CDMO partner.

The company also recertified to upgraded ISO 27001:2022 (Information Security Management System) and ISO 27017:2015 (Information Security for Cloud Services), displaying continued efforts to maintain the highest standards of information and cloud security as well as data protection for clients and stakeholders.

The ISO 27000 family is the most recognized global set of standards for managing information security and privacy management. Samsung Biologics has been implementing best practices and principles in accordance with international standards to enhance client satisfaction and build further trust.

"We're pleased to obtain certification for compliance as it's a recognition of our unwavering focus to meeting the highest standards to build deeper trust with our clients and strengthen business competitiveness," said John Rim, CEO and President of Samsung Biologics.

"Along with existing ISO certifications, we will continue to take the extra mile to strengthen ethical management while maintaining the highest security and privacy standards," Rim added.

Samsung Biologics continues to be certified across other areas, including anti-bribery management, quality management, and business continuity management.